Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06845878 · ClinicalTrials.gov registry record · Phase 1

A Chatbot to Support Substance Use Recovery

A Phase 1 study of Opiate Substitution Treatment and Opiate-Related Disorders, sponsored by Dimagi.

Recruiting
Registry status
Phase 1
Development phase
55
Enrollment target
1
Study location

NCT06845878: Recruiting Phase 1 study of Opiate Substitution Treatment and Opiate-Related Disorders, sponsored by Dimagi.

NCT06845878 is a Phase 1 study of Opiate Substitution Treatment and Opiate-Related Disorders that is actively recruiting participants, run by Dimagi. The registered enrollment target is 55 participants, below the 415-participant average among 3 other Opiate Substitution Treatment trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06845878, a Phase 1 study of Opiate Substitution Treatment and Opiate-Related Disorders, is actively recruiting participants, sponsored by Dimagi.

RECRUITING
Registry status
Phase 1
Development phase
55 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn if/how an AI chatbot can support patients who in recovery for substance use, specifically those who are receiving medication for opioid use disorder. Can the chatbot help lower drug use? Can the chatbot help improve clinical appointment adherence? Can the chatbot help patients build self-efficacy in leading their own recovery journey? Will the chatbot help reduce workload burden for primary care teams? Can the chatbot serve as a safe, useful and engaging tool to support patients? Researchers will investigate the effects of using a chatbot to support follow-up care for patients in opioid use recovery. Participants will: * Receive access to a chatbot for 12 weeks that they can use to prepare for upcoming clinical appointments, find community resources, learn about urge-surfing and wellness techniques, and query for assistance with other recovery-related information and tasks * Complete surveys and provide user feedback

Primary Outcome

Addiction Severity Index (ASI) Drugs composite score; Scored 0-7 with higher scores indicating increasing severity

Conditions Studied

Opiate Substitution Treatment Opiate-Related Disorders

Interventions

  • OTHER chatbot

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2025-03-07
Est. Completion 2025-09
Phase Phase 1
Dimagi

4 total trials

What NCT06845878 shows while recruiting

NCT06845878 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 415-participant average among 3 other Opiate Substitution Treatment trials with a reported enrollment target (87% lower).

The record links to 2 conditions, with Opiate Substitution Treatment appearing as the primary indexed condition, and to 1 intervention - of which chatbot is the first listed.

NCT06845878 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06845878 about?

NCT06845878 is a clinical study titled "A Chatbot to Support Substance Use Recovery". The goal of this clinical trial is to learn if/how an AI chatbot can support patients who in recovery for substance use, specifically those who are receiving medication for opioid use disorder. Can the chatbot help lower drug use? Can the chatbot help improve clinical appointment adherence? Can the...

What is the current status of trial NCT06845878?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2025-03-07. Estimated completion is 2025-09.

What conditions does trial NCT06845878 study?

This clinical trial studies the following conditions: Opiate Substitution Treatment, Opiate-Related Disorders.

What interventions are being tested in trial NCT06845878?

The interventions under investigation include: chatbot (OTHER).

Who is sponsoring clinical trial NCT06845878?

This trial is sponsored by Dimagi, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06845878 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Opiate Substitution Treatment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01638676 · 55 participants · Phase 1

    A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

  • NCT01906385 · 55 participants · Phase 1

    Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

  • NCT03007030 · 55 participants · Phase 2

    Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

  • NCT03152058 · 55 participants · Phase 2

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06845878

Source: ClinicalTrials.gov NCT06845878, the US trial registry maintained by the National Library of Medicine. NCT06845878 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.